Evidence map›Paper›PMID 32699318›Full record

ReviewNature reviews. Urology2020

The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs.

Michelle M Kouspou, Jenna E Fong, Nadine Brew, Sarah T F Hsiao, Seanna L Davidson, Peter L Choyke, Tony Crispino, Suneil Jain, Guido W Jenster, Beatrice S Knudsen and 5 more

Open access · hybridAbstract readConsensus StatementReview
In one paragraph

Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Complexities of Prostate Cancer.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 6 countries.

Michelle M KouspouMovember, Melbourne, Victoria, Australia.
Jenna E FongMovember, Melbourne, Victoria, Australia.
Nadine BrewMovember, Melbourne, Victoria, Australia.
Sarah T F HsiaoMovember, Melbourne, Victoria, Australia.ORCID 0000-0002-8455-2763
Seanna L DavidsonThe Systems School, Melbourne, Victoria, Australia.
Peter L ChoykeCenter for Cancer Research, National Institute of Health/National Cancer Institute, Bethesda, MD, USA.
Tony CrispinoSWOG Cancer Research Network, Prostate Cancer Patient Advocate, Portland, OR, USA.
Suneil JainPatrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
Guido W JensterDepartment of Urology, Erasmus Medical Center, Rotterdam, Netherlands.ORCID 0000-0002-8658-2552
Beatrice S KnudsenUniversity of Utah, Salt Lake City, UT, USA.
Jeremy L MillarAlfred Health Radiation Oncology, The Alfred Hospital School of Science, Melbourne, Victoria, Australia.ORCID 0000-0001-8202-8602
Nicole MittmannSunnybrook Research Institute, Sunnybrook Health Science Centre, University of Toronto, Toronto, Ontario, Canada.
Charles J RyanUniversity of Minnesota, Minneapolis, MN, USA.
Bertrand TombalUniversité Catholique de Louvain, Louvain-la-Neuve, Belgium.
Mark BuzzaMovember, Melbourne, Victoria, Australia. markbuzza@gmail.com.ORCID 0000-0003-4343-0812
Movember Foundation · AUErasmus MC · NLEuropean Organisation for Research and Treatment of Cancer · BEMelbourne School of Theology · AUNational Cancer Institute · USQueen's University Belfast · GBSunnybrook Health Science Centre · CASWOG Cancer Research Network · USThe Alfred Hospital · AUUniversity of Minnesota · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a heterogeneous cancer with widely varying levels of morbidity and mortality. Approaches to prostate cancer screening, diagnosis, surveillance, treatment and management differ around the world. To identify the highest priority research needs across the prostate cancer biomedical research domain, Movember conducted a landscape analysis with the aim of maximizing the effect of future research investment through global collaborative efforts and partnerships. A global Landscape Analysis Committee (LAC) was established to act as an independent group of experts across urology, medical oncology, radiation oncology, radiology, pathology, translational research, health economics and patient advocacy. Men with prostate cancer and thought leaders from a variety of disciplines provided a range of key insights through a range of interviews. Insights were prioritized against predetermined criteria to understand the areas of greatest unmet need. From these efforts, 17 research needs in prostate cancer were agreed on and prioritized, and 3 received the maximum prioritization score by the LAC: first, to establish more sensitive and specific tests to improve disease screening and diagnosis; second, to develop indicators to better stratify low-risk prostate cancer for determining which men should go on active surveillance; and third, to integrate companion diagnostics into randomized clinical trials to enable prediction of treatment response. On the basis of the findings from the landscape analysis, Movember will now have an increased focus on addressing the specific research needs that have been identified, with particular investment in research efforts that reduce disease progression and lead to improved therapies for advanced prostate cancer.

Indexed as

Biomedical ResearchNeeds AssessmentHumansMaleProstatic Neoplasms

Identifiers

PMID32699318
PMCPMC7462750
OpenAlexW3044887114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.